|
ISRCTN
|
ISRCTN14200211
|
|
ClinicalTrials.gov identifier
|
|
|
Public title
|
Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis
|
|
Scientific title
|
|
|
Acronym
|
N/A
|
|
Serial number at source
|
vit K 2006
|
|
Study hypothesis
|
Vitamin K supplementation improves markers of bone turnover and bone density in adolescents and adults with cystic fibrosis (CF).
|
|
Ethics approval
|
Ethics approval received from the Wandsworth Research Ethics Committee on the 11th August 2006 (protocol v4), 18th May 2007 (amendments protocol v5) and 3rd August 2007 (amendments protocol v6).
|
|
Study design
|
Randomised double-blind placebo-controlled study
|
|
Countries of recruitment
|
United Kingdom
|
|
Disease/condition/study domain
|
Bone health in cystic fibrosis
|
|
Participants - inclusion criteria
|
1. Patients with a diagnosis of CF (positive sweat test or genotype testing)
2. Patients aged greater than 16 years (post pubertal-stage IV Tanner), either sex
3. Patients are pancreatic insufficient (i.e. with a positive faecal elastase test, and requiring pancreatic enzyme supplementation)
4. No evidence of overt liver disease (not on ursodeoxycholic acid)
|
|
Participants - exclusion criteria
|
1. Patients already taking vitamin K supplementation
2. Patients with osteoporosis or osteopaenia and taking bisphosphonates
3. Patients with abnormally low vitamin D levels (less than 30 µg)
4. Patients on maintenance oral corticosteroids
5. Patients who are considered to have very sedentary lifestyle or follow a rigorous exercise training programme
6. Patients with overt liver disease
7. Patients who do not consent to participate
8. Patients with a life expectancy of less than 12 months
9. Patients who are non-compliant with maintenance therapies
|
|
Anticipated start date
|
02/01/2007
|
|
Anticipated end date
|
09/02/2009
|
|
Status of trial
|
Ongoing
|
|
Patient information material
|
Not available in web format, please use the contact details below to request a patient information sheet
|
|
Target number of participants
|
40
|
|
Interventions
|
1. 10 mg of menadiol phosphate (water soluble form of vitamin K) once daily (o.d.) orally for 12 months
2. Matching placebo for 12 months
Total duration of treatment and follow-up: 12 months for both arms.
|
|
Primary outcome measure(s)
|
The between-groups difference in the ratio of undercarboxylated osteocalcin to total osteocalcin, measured prior to supplementation starting and at the end of the 12 months supplementation.
|
|
Secondary outcome measure(s)
|
The between-group differences in:
1. Total osteocalcin
2. Undercarboxylated osteocalcin
3. N Terminal X (marker of bone resorption)
4. Bone specific alkaline phosphatase
5. Serum vitamin D
6. Calcium
7. Dual energy x-ray absorptiometry (DEXA) scan z and t scores of lumbar spine and femoral neck (scores adjusted for age, height and sex)
Measured prior to supplementation starting and at the end of the 12 months supplementation.
|
|
Sources of funding
|
Barts and the London NHS Trust (UK) - Internally funded from Nursing, Midwifering and Allied Health Profession research grant
|
|
Trial website
|
|
|
Publications
|
|
|
Contact name
|
Dr
Lieske
Kuitert
|
|
Address
|
Department of Respiratory Medicine
London Chest Hospital
Bonner Road
|
|
City/town
|
London
|
|
Zip/Postcode
|
E2 9JX
|
|
Country
|
United Kingdom
|
|
Sponsor
|
Barts and the London NHS Trust (UK)
|
|
Address
|
Research and Development Department
24 - 26 Walden Street
Whitechapel
|
|
City/town
|
London
|
|
Zip/Postcode
|
E1 2AN
|
|
Country
|
United Kingdom
|
|
Sponsor website:
|
http://www.bartsandthelondon.org.uk/
|
|
Date applied
|
02/04/2008
|
|
Last edited
|
09/05/2008
|
|
Date ISRCTN assigned
|
09/05/2008
|